# EDGAR Filing Document

**Accession Number:** 0001428336
**File Stem:** 0001428336-26-000009
**Filing Date:** 2026-3
**Character Count:** 41091
**Document Hash:** 8d0e912674979152ce2c8816815e47d1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001428336-26-000009.hdr.sgml**: 20260317

**ACCESSION NUMBER**: 0001428336-26-000009

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20260317

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260317

**DATE AS OF CHANGE**: 20260317

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** HEALTHEQUITY, INC.
- **CENTRAL INDEX KEY:** 0001428336
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-BUSINESS SERVICES, NEC [7389]
- **ORGANIZATION NAME:** 07 Trade & Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0131

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36568
- **FILM NUMBER:** 26761667

**BUSINESS ADDRESS:**
- **STREET 1:** 15 WEST SCENIC POINTE DRIVE
- **STREET 2:** SUITE 100
- **CITY:** DRAPER
- **STATE:** UT
- **ZIP:** 84020
- **BUSINESS PHONE:** 801-727-1000

**MAIL ADDRESS:**
- **STREET 1:** 15 WEST SCENIC POINTE DRIVE
- **STREET 2:** SUITE 100
- **CITY:** DRAPER
- **STATE:** UT
- **ZIP:** 84020

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** HEALTHEQUITY INC
- **DATE OF NAME CHANGE:** 20080227

?xml version='1.0' encoding='ASCII'? hqy-20260317

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 8-K** 

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of**

**The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported)**

**March 17, 2026** 

**HEALTHEQUITY, INC.**<br>

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-36568** | **52-2383166** |
| **(State or other jurisdiction of**<br>**incorporation or organization)** | **(Commission File Number)** | **(I.R.S. Employer**<br>**Identification Number)** |

---

**15 West Scenic Pointe Drive** 

**Suite 100** 

**Draper, Utah 84020** 

**(801) 727-1000** 

**(Address, including Zip Code, and Telephone Number, including Area Code, of Registrant's Principal Executive Offices)**

**Not Applicable**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common stock, par value $0.0001 per share | HQY | The NASDAQ Global Select Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 2.02&nbsp;&nbsp;&nbsp;&nbsp;Results of Operations and Financial Condition**

On March 17, 2026, HealthEquity, Inc. issued a press release attached as Exhibit 99.1 to this current report on Form 8-K.

The information in Exhibit 99.1 is being furnished to the Securities and Exchange Commission and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

**Item 9.01&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits**

(d) Exhibits

---

| | |
|:---|:---|
| **<u>Exhibit No.</u>** | **<u>Description</u>** |
| 99.1 | <u>[Press release issued by HealthEquity, Inc. dated March 17, 2026](hqyq4fy26earningsrelease.htm)</u> |
| 104 | Cover Page Interactive Data File (formatted in Inline XBRL) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | **HEALTHEQUITY, INC.** | **HEALTHEQUITY, INC.** |
| Date: March 17, 2026 | By: | /s/ James Lucania |
|  | Name: | James Lucania |
|  | Title: | Executive Vice President and Chief Financial Officer |

---

## Exhibit 99.1

**HealthEquity Reports Record Revenue, Earnings and New HSAs From Sales for Fourth Quarter and Year Ended January 31, 2026, Resulting in Raised Fiscal 2027 Outlook**

**Highlights of the fiscal year include:**

• Revenue increased 9% to $1.31 billion.

• Net income increased 123% to $215.2 million, and net income margin increased to 16% from 8% last year.

• Net income per diluted share rose to $2.46 from $1.09 one year ago, and non-GAAP net income per diluted share increased 28% to $4.00.

• Adjusted EBITDA increased 20% to $566.0 million, and Adjusted EBITDA margin increased to 43% from 39% last year.

• Total HSA Assets grew 14% to $36.5 billion.

• Returned $301.7 million to shareholders through stock repurchases.

• Further reduced HSA cash repricing risk with a cumulative $2.35 billion 5-year Treasury bond hedge at 3.92%.

**Highlights of the fourth quarter include:**

• Revenue increased 7% to $334.6 million.

• Net income increased 89% to $49.7 million, and net income margin increased to 15% from 8% last year.

• Net income per diluted share rose to $0.58 from $0.30 one year ago, and non-GAAP net income per diluted share increased 38% to $0.95.

• Adjusted EBITDA increased 23% to $132.9 million, and Adjusted EBITDA margin increased to 40% from 35% last year.

• Returned $81.7 million to shareholders through stock repurchases.

**DRAPER, Utah – March 17, 2026** – HealthEquity, Inc. (NASDAQ: HQY) ("HealthEquity" or the "Company"), a leader in administering health savings accounts ("HSAs") and complementary consumer-directed benefits ("CDBs"), today announced financial results for its fiscal year and fourth quarter ended January 31, 2026.

"We are raising our fiscal 2027 guidance after delivering record new HSAs from sales and significant margin expansion," said Scott Cutler, President and CEO of HealthEquity. "Adjusted EBITDA increased 23% in the fourth quarter with Adjusted EBITDA margin expanding more than 500 basis points to 40%, reflecting meaningful operating leverage. We added one million new HSAs from sales for the second consecutive year and ended fiscal 2026 with 17.8 million total accounts and over $36 billion in HSA assets, positioning us for continued growth."

**Fiscal year financial results**

Revenue for the fiscal year ended January 31, 2026 was $1.31 billion, an increase of 9% compared to $1.20 billion for the fiscal year ended January 31, 2025. Revenue this year included: service revenue of $485.0 million, custodial revenue of $636.8 million, and interchange revenue of $191.6 million.

HealthEquity reported net income of $215.2 million, or $2.46 per diluted share, and non-GAAP net income of $349.8 million, or $4.00 per diluted share, for the fiscal year ended January 31, 2026. The Company reported net income of $96.7 million, or $1.09 per diluted share, and non-GAAP net income of $277.3 million, or $3.12 per diluted share, for the fiscal year ended January 31, 2025.

Adjusted EBITDA was $566.0 million for the fiscal year ended January 31, 2026, an increase of 20% compared to $471.8 million for the fiscal year ended January 31, 2025. Adjusted EBITDA was 43% of revenue, compared to 39% for the fiscal year ended January 31, 2025.

As of January 31, 2026, HealthEquity had $318.9 million of cash and cash equivalents and $957.4 million of outstanding debt, net of issuance costs. This compares to $295.9 million in cash and cash equivalents and $1.06 billion of outstanding debt as of January 31, 2025.

**Fourth quarter financial results**

Revenue for the fourth quarter ended January 31, 2026 was $334.6 million, an increase of 7% compared to $311.8 million for the fourth quarter ended January 31, 2025. Revenue this quarter included: service revenue of $127.1 million, custodial revenue of $161.4 million, and interchange revenue of $46.1 million.

HealthEquity reported net income of $49.7 million, or $0.58 per diluted share, and non-GAAP net income of $81.8 million, or $0.95 per diluted share, for the fourth quarter ended January 31, 2026. The Company reported net income of

------

$26.4 million, or $0.30 per diluted share, and non-GAAP net income of $61.3 million, or $0.69 per diluted share, for the fourth quarter ended January 31, 2025.

Adjusted EBITDA was $132.9 million for the fourth quarter ended January 31, 2026, an increase of 23% compared to $107.8 million for the fourth quarter ended January 31, 2025. Adjusted EBITDA was 40% of revenue, compared to 35% for the fourth quarter ended January 31, 2025.

**Account and asset metrics**

HSAs as of January 31, 2026 were 10.6 million, an increase of 7% year over year, including 832,000 HSAs with investments, an increase of 10% year over year. Total Accounts as of January 31, 2026 were 17.8 million, including 7.2 million complementary CDBs.

Total HSA Assets as of January 31, 2026 were $36.5 billion, an increase of 14% year over year. Total HSA Assets included $18.0 billion of HSA cash and $18.5 billion of HSA investments. Client-held funds, which are deposits held on behalf of our Clients to facilitate administration of our CDBs, and from which we generate custodial revenue, were $1.1 billion as of January 31, 2026.

**Stock repurchase program**

The Company repurchased 3.3 million shares of its common stock for $301.7 million during the fiscal year ended January 31, 2026, including 0.9 million shares for $81.7 million during the fourth quarter ended January 31, 2026. As of January 31, 2026, $177.7 million of common stock remained authorized for repurchase under the Company's stock repurchase program.

**Business outlook**

For the fiscal year ending January 31, 2027, management expects revenues of $1.405 billion to $1.415 billion. Its outlook for net income is between $239 million and $246 million, resulting in net income of $2.78 to $2.85 per diluted share. Its outlook for non-GAAP net income, calculated using the method described below, is between $392 million and $400 million, resulting in non-GAAP net income per diluted share of $4.56 to $4.65 (based on an estimated 86 million weighted-average shares outstanding). Management expects Adjusted EBITDA of $618 million to $628 million.

See "Non-GAAP financial information" below for definitions of our Adjusted EBITDA and non-GAAP net income. A reconciliation of the non-GAAP financial measures used throughout this release to the most comparable GAAP financial measures is included with the financial tables at the end of this release.

**Conference call**

HealthEquity management will host a conference call at 4:30 pm (Eastern Time) on Tuesday, March 17, 2026 to discuss the fiscal 2026 fourth quarter and year-end results. The conference call will be accessible by dialing 1-833-630-1956, or 1-412-317-1837 for international callers, and referencing conference ID "HealthEquity." A live audio webcast of the call will be available on the investor relations section of our website at http://ir.healthequity.com.

**Non-GAAP financial information** 

To supplement our financial information presented on a GAAP basis, we disclose non-GAAP financial measures, including Adjusted EBITDA, non-GAAP net income, and non-GAAP net income per diluted share.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted EBITDA is earnings before interest, taxes, depreciation and amortization, amortization of acquired intangible assets, stock-based compensation expense, merger integration expenses, acquisition costs, gains and losses on equity securities, amortization of incremental costs to obtain a contract, costs associated with unused office space, and certain other non-operating items.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Non-GAAP net income is calculated by adding back to GAAP net income before income taxes the following items: amortization of acquired intangible assets, stock-based compensation expense, merger integration expenses, acquisition costs, gains and losses on equity securities, costs associated with unused office space, and losses on extinguishment of debt, and subtracting a non-GAAP tax provision using a normalized non-GAAP tax rate.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Non-GAAP net income per diluted share is calculated by dividing non-GAAP net income by diluted weighted-average shares outstanding.

Non-GAAP financial measures should be considered in addition to results prepared in accordance with GAAP and should not be considered as a substitute for, or superior to, GAAP results. We believe that these non-GAAP financial measures provide useful information to management and investors regarding certain financial and business trends

------

relating to the Company's financial condition and results of operations. The Company cautions investors that non-GAAP financial information, by its nature, departs from GAAP; accordingly, its use can make it difficult to compare current results with results from other reporting periods and with the results of other companies. In addition, while amortization of acquired intangible assets is being excluded from non-GAAP financial measures, the revenue generated from those acquired intangible assets is not excluded. Whenever we use these non-GAAP financial measures, we provide a reconciliation of the applicable non-GAAP financial measure to the most closely applicable GAAP financial measure. Investors are encouraged to review the related GAAP financial measures and the reconciliation of the non-GAAP financial measures to their most directly comparable GAAP financial measure as detailed in the tables below.

**About HealthEquity**

HealthEquity and its subsidiaries administer HSAs and other consumer-directed benefits for more than 17 million accounts in partnership with employers, benefits advisors, and health and retirement plan providers who share our mission to save and improve lives by empowering healthcare consumers. For more information, visit www.healthequity.com.

**Forward-looking statements** 

This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding our industry, business strategy, plans, goals and expectations concerning our markets and market position, product expansion, future operations, expenses and other results of operations, revenue, margins, profitability, acquisition synergies, future efficiencies, tax rates, capital expenditures, liquidity and capital resources and other financial and operating information. When used in this discussion, the words "may," "believes," "intends," "seeks," "aims," "anticipates," "plans," "estimates," "expects," "should," "assumes," "continues," "could," "will," "future" and the negative of these or similar terms and phrases are intended to identify forward-looking statements in this press release.

Forward-looking statements reflect our current expectations regarding future events, results or outcomes. These expectations may or may not be realized. Although we believe the expectations reflected in the forward-looking statements are reasonable, we can give you no assurance these expectations will prove to be correct. Some of these expectations may be based upon assumptions, data or judgments that prove to be incorrect. Actual events, results and outcomes may differ materially from our expectations due to a variety of known and unknown risks, uncertainties and other factors. Although it is not possible to identify all of these risks and factors, they include, among others, risks related to the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to adequately place and safeguard our custodial assets, or the failure of any of our depository or insurance company partners;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to compete effectively in a rapidly evolving healthcare and benefits administration industry;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our dependence on the continued availability and benefits of tax-advantaged HSAs and other CDBs;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the impact of fraudulent account activity involving our member accounts or our third-party service providers on our reputation and financial results;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to successfully identify, acquire and integrate additional portfolio purchases or acquisition targets;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the significant competition we face and may face in the future, including from those with greater resources than us;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our reliance on the availability and performance of our technology and communications systems;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• potential future cybersecurity breaches of our technology and communications systems and other data interruptions, including resulting costs and liabilities, reputational damage and loss of business;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the current uncertain healthcare environment, including changes in healthcare programs and expenditures and related regulations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to comply with current and future privacy, healthcare, tax, ERISA, investment adviser and other laws applicable to our business;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our reliance on partners and third-party vendors for distribution and important services;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to develop and implement updated features for our technology platforms and communications systems; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our reliance on our management team and key team members.

For a detailed discussion of these and other risk factors, please refer to the risks detailed in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the fiscal year ended January 31, 2026. Past performance is not necessarily indicative of future results. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or

------

otherwise. Forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

**Investor Relations Contact**

Richard Putnam

801-727-1000

rputnam@healthequity.com

------

**HealthEquity, Inc. and subsidiaries**

**Consolidated balance sheets (unaudited)**

---

| | | |
|:---|:---|:---|
| **(in thousands, except par value)** | **January 31, 2026** | **January 31, 2025** |
| **Assets** | | |
| Current assets |  |  |
| &nbsp;&nbsp;&nbsp;Cash and cash equivalents | $318927 | $295948 |
| &nbsp;&nbsp;&nbsp;Accounts receivable, net of allowance for doubtful accounts of $924 and $2,070 as of January 31, 2026 and 2025, respectively | 123696 | 118006 |
| &nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 69658 | 63795 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 512281 | 477749 |
| &nbsp;&nbsp;&nbsp;Property and equipment, net | 3177 | 3239 |
| &nbsp;&nbsp;&nbsp;Operating lease right-of-use assets | 36310 | 43185 |
| &nbsp;&nbsp;&nbsp;Intangible assets, net | 1097172 | 1204658 |
| &nbsp;&nbsp;&nbsp;Goodwill | 1648145 | 1648145 |
| &nbsp;&nbsp;&nbsp;Other assets | 83247 | 71574 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | $3380332 | $3448550 |
| **Liabilities and stockholders' equity** |  |  |
| Current liabilities |  |  |
| &nbsp;&nbsp;&nbsp;Accounts payable | $12159 | $14361 |
| &nbsp;&nbsp;&nbsp;Accrued compensation | 60392 | 69330 |
| &nbsp;&nbsp;&nbsp;Accrued liabilities | 74388 | 62631 |
| &nbsp;&nbsp;&nbsp;Operating lease liabilities | 9911 | 10001 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 156850 | 156323 |
| Long-term liabilities |  |  |
| &nbsp;&nbsp;&nbsp;Long-term debt, net of issuance costs | 957379 | 1056301 |
| &nbsp;&nbsp;&nbsp;Operating lease liabilities, non-current | 34190 | 42219 |
| &nbsp;&nbsp;&nbsp;Other long-term liabilities | 31007 | 22962 |
| &nbsp;&nbsp;&nbsp;Deferred tax liability | 93710 | 55834 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total long-term liabilities | 1116286 | 1177316 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | 1273136 | 1333639 |
| Commitments and contingencies |  |  |
| Stockholders' equity |  |  |
| &nbsp;&nbsp;&nbsp;Preferred stock, $0.0001 par value, 100,000 shares authorized, no shares issued and outstanding as of January 31, 2026 and 2025 |  |  |
| &nbsp;&nbsp;&nbsp;Common stock, $0.0001 par value, 900,000 shares authorized, 85,007 and 86,536 shares issued and outstanding as of January 31, 2026 and 2025, respectively | 8 | 9 |
| Additional paid-in capital | 1916989 | 1905628 |
| Accumulated earnings | 195906 | 209274 |
| Accumulated other comprehensive loss | (5707) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total stockholders' equity | 2107196 | 2114911 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities and stockholders' equity | $3380332 | $3448550 |

---

------

**HealthEquity, Inc. and subsidiaries**

**Consolidated statements of operations (unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended January 31,** | **Three months ended January 31,** | **Year ended January 31,** | **Year ended January 31,** |
|<br>**(in thousands, except per share data)** | **2026** | **2025** | **2026** | **2025** |
| Revenue |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Service revenue | $127079 | $124209 | $485022 | $478317 |
| &nbsp;&nbsp;&nbsp;&nbsp;Custodial revenue | 161402 | 144133 | 636800 | 545414 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interchange revenue | 46105 | 43475 | 191607 | 176043 |
| &nbsp;&nbsp;&nbsp; Total revenue | 334586 | 311817 | 1313429 | 1199774 |
| Cost of revenue |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Service costs | 88457 | 105466 | 328507 | 351588 |
| &nbsp;&nbsp;&nbsp;&nbsp;Custodial costs | 11058 | 10269 | 43821 | 39675 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interchange costs | 6924 | 7039 | 27985 | 31252 |
| &nbsp;&nbsp;&nbsp; Total cost of revenue | 106439 | 122774 | 400313 | 422515 |
| Gross profit | 228147 | 189043 | 913116 | 777259 |
| Operating expenses |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Sales and marketing | 24923 | 23084 | 95240 | 90739 |
| &nbsp;&nbsp;&nbsp;&nbsp;Technology and development | 70354 | 64654 | 262510 | 239513 |
| &nbsp;&nbsp;&nbsp;&nbsp;General and administrative | 33527 | 29975 | 119933 | 132260 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of acquired intangible assets | 26948 | 27002 | 107953 | 111878 |
| &nbsp;&nbsp;&nbsp;Merger integration | 1324 | 2178 | 5024 | 40535 |
| &nbsp;&nbsp;&nbsp; Total operating expenses | 157076 | 146893 | 590660 | 614925 |
| Income from operations | 71071 | 42150 | 322456 | 162334 |
| Other expense |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Interest expense | (13269) | (15257) | (57131) | (60634) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other income, net | 3097 | 3068 | 12107 | 14334 |
| &nbsp;&nbsp;&nbsp;&nbsp; Total other expense | (10172) | (12189) | (45024) | (46300) |
| Income before income taxes | 60899 | 29961 | 277432 | 116034 |
| Income tax provision | 11159 | 3596 | 62231 | 19331 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income and comprehensive income | $49740 | $26365 | $215201 | $96703 |
| Net income per share: |  |  |  |  |
| &nbsp;&nbsp;&nbsp; Basic | $0.58 | $0.30 | $2.50 | $1.11 |
| &nbsp;&nbsp;&nbsp; Diluted | $0.58 | $0.30 | $2.46 | $1.09 |
| Weighted-average number of shares used in computing net income per share: |  |  |  |  |
| &nbsp;&nbsp;&nbsp; Basic | 85344 | 86677 | 86132 | 86870 |
| &nbsp;&nbsp;&nbsp; Diluted | 86290 | 88614 | 87473 | 88828 |

---

------

**HealthEquity, Inc. and subsidiaries**

**Consolidated statements of comprehensive income (unaudited)**

---

| | | | |
|:---|:---|:---|:---|
| | **Year ended January 31,** | **Year ended January 31,** | **Year ended January 31,** |
|<br>**(in thousands, except per share data)** | **2026** | **2025** | **2024** |
| Net income | $215201 | $96703 | $55712 |
| Other comprehensive loss |  |  |  |
| &nbsp;&nbsp;&nbsp;Cash flow hedges |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net unrealized losses | (5695) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reclassification of net gains included in net income | (12) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net change, net of income tax benefit of $1,854 for the year ended January 31, 2026 | (5707) |  |  |
| Total other comprehensive loss | (5707) |  |  |
| Comprehensive income | $209494 | $96703 | $55712 |

---

------

**HealthEquity, Inc. and subsidiaries**

**Consolidated statements of cash flows (unaudited)**

---

| | | |
|:---|:---|:---|
| | **Year ended January 31,** | **Year ended January 31,** |
|<br>**(in thousands)** | **2026** | **2025** |
| Cash flows from operating activities: |  |  |
| Net income | $215201 | $96703 |
| Adjustments to reconcile net income to net cash provided by operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;Depreciation and amortization | 154657 | 162451 |
| &nbsp;&nbsp;&nbsp;Stock-based compensation | 73063 | 96425 |
| &nbsp;&nbsp;&nbsp;Amortization of debt issuance costs | 1078 | 2067 |
| &nbsp;&nbsp;&nbsp;Amortization of gains on derivatives | (16) |  |
| &nbsp;&nbsp;&nbsp;Loss on extinguishment of debt |  | 1576 |
| &nbsp;&nbsp;&nbsp;Deferred taxes | 39730 | (12836) |
| &nbsp;&nbsp;&nbsp; Changes in operating assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable | (5690) | (13113) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current and non-current assets | (12663) | (11790) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating lease right-of-use assets | 6785 | 6664 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued compensation | (8806) | 17758 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable, accrued liabilities, and other current liabilities | 1708 | 8888 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating lease liabilities, non-current | (8001) | (7779) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other long-term liabilities | 48 | (7158) |
| Net cash provided by operating activities | 457094 | 339856 |
| Cash flows from investing activities: |  |  |
| &nbsp;&nbsp;&nbsp;Purchases of software and capitalized software development costs | (46515) | (51129) |
| &nbsp;&nbsp;&nbsp;Purchases of property and equipment | (1969) | (2084) |
| &nbsp;&nbsp;&nbsp;Acquisitions of HSA portfolios | (293) | (452241) |
| &nbsp;&nbsp;&nbsp;Settlement of derivatives, net | 1637 |  |
| Net cash used in investing activities | (47140) | (505454) |
| Cash flows from financing activities: |  |  |
| &nbsp;&nbsp;&nbsp;Principal payments on long-term debt | (100000) | (561875) |
| &nbsp;&nbsp;&nbsp;Repurchases of common stock | (299254) | (121493) |
| &nbsp;&nbsp;&nbsp;Proceeds from long-term debt |  | 736875 |
| &nbsp;&nbsp;&nbsp;Payment of debt issuance costs |  | (3748) |
| &nbsp;&nbsp;&nbsp;Settlement of client-held funds obligation, net | 867 | (1620) |
| &nbsp;&nbsp;&nbsp;Proceeds from exercise of common stock options | 11412 | 9428 |
| Net cash provided by (used in) financing activities | (386975) | 57567 |
| Increase (decrease) in cash and cash equivalents | 22979 | (108031) |
| Beginning cash and cash equivalents | 295948 | 403979 |
| Ending cash and cash equivalents | $318927 | $295948 |

---

------

**HealthEquity, Inc. and subsidiaries**

**Consolidated statements of cash flows (unaudited) (continued)**

---

| | | |
|:---|:---|:---|
| | **Year ended January 31,** | **Year ended January 31,** |
|<br>**(in thousands)** | **2026** | **2025** |
| Supplemental cash flow data: |  |  |
| &nbsp;&nbsp;&nbsp;Interest expense paid in cash | $52245 | $58587 |
| &nbsp;&nbsp;&nbsp;Income tax payments, net | 8042 | 26069 |
| Supplemental disclosures of non-cash investing and financing activities: |  |  |
| &nbsp;&nbsp;&nbsp;Purchases of software and capitalized software development costs included in accounts payable, accrued liabilities, or accrued compensation | 4332 | 5971 |
| &nbsp;&nbsp;&nbsp;Purchases of property and equipment included in accounts payable or accrued liabilities | 16 | 45 |
| &nbsp;&nbsp;&nbsp;Repurchases of common stock included in accrued liabilities | 3174 | 754 |
| &nbsp;&nbsp;&nbsp;Non-cash purchase consideration related to acquisitions of HSA portfolios |  | 20325 |
| &nbsp;&nbsp;&nbsp;Settlement of derivatives included in other current assets | 2465 |  |
| &nbsp;&nbsp;&nbsp;Exercise of common stock options receivable |  | 10 |

---

**Stock-based compensation expense (unaudited)**

Total stock-based compensation expense included in the consolidated statements of operations and comprehensive income is as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended January 31,** | **Three months ended January 31,** | **Year ended January 31,** | **Year ended January 31,** |
|<br>**(in thousands)** | **2026** | **2025** | **2026** | **2025** |
| Cost of revenue | $3002 | $3745 | $12686 | $14955 |
| Sales and marketing | 3203 | 3750 | 13093 | 15623 |
| Technology and development | 5534 | 6255 | 23167 | 25002 |
| General and administrative | 7378 | 7958 | 24117 | 40845 |
| Total stock-based compensation expense | $19117 | $21708 | $73063 | $96425 |

---

**Total Accounts (unaudited)**

---

| | | | |
|:---|:---|:---|:---|
| **(in thousands, except percentages)** | **January 31, 2026** | **January 31, 2025** | **% Change** |
| HSAs | 10570 | 9889 | 7% |
| New HSAs from sales - Quarter-to-date | 553 | 471 | 17% |
| New HSAs from sales - Year-to-date | 1040 | 1040 | 0% |
| New HSAs from acquisitions - Year-to-date |  | 616 | \* |
| HSAs with investments | 832 | 753 | 10% |
| CDBs | 7221 | 7144 | 1% |
| Total Accounts | 17791 | 17033 | 4% |
| Average Total Accounts - Quarter-to-date | 17462 | 16677 | 5% |
| Average Total Accounts - Year-to-date | 17220 | 16302 | 6% |

---

**\***Not meaningful

**HSA assets (unaudited)**

---

| | | | |
|:---|:---|:---|:---|
| **(in millions, except percentages)** | **January 31, 2026** | **January 31, 2025** | **% Change** |
| HSA cash | $17982 | $17435 | 3% |
| HSA investments | 18482 | 14676 | 26% |
| Total HSA Assets | 36464 | 32111 | 14% |
| Average daily HSA cash - Quarter-to-date | 17090 | 16634 | 3% |
| Average daily HSA cash - Year-to-date | 17082 | 16206 | 5% |

---

------

**HSA cash maturity schedule**

The following table summarizes the amount of HSA cash held by our depository partners and insurance company partners that is expected to reprice by fiscal year and the respective average annualized yield currently earned on that HSA cash as of January 31, 2026:

---

| | | |
|:---|:---|:---|
| **Year ending January 31, (in billions, except percentages)** | **HSA cash expected to reprice** | **Average annualized yield** |
| 2027 | $4.5 | 1.9% |
| 2028 | 2.3 | 4.0% |
| 2029 | 1.7 | 3.6% |
| 2030 | 2.4 | 4.4% |
| Thereafter | 6.4 | 4.2% |
| &nbsp;&nbsp;&nbsp;Total (1) | $17.3 | 3.6% |

---

(1)Excludes $0.7 billion of HSA cash held in floating-rate contracts as of January 31, 2026.

**Client-held funds (unaudited)**

---

| | | | |
|:---|:---|:---|:---|
| **(in millions, except percentages)** | **January 31, 2026** | **January 31, 2025** | **% Change** |
| Client-held funds | $1090 | $896 | 22% |
| Average daily Client-held funds - Quarter-to-date | 879 | 798 | 10% |
| Average daily Client-held funds - Year-to-date | 864 | 817 | 6% |

---

**Net income reconciliation to Adjusted EBITDA (unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended January 31,** | **Three months ended January 31,** | **Year ended January 31,** | **Year ended January 31,** |
|<br>**(in thousands)** | **2026** | **2025** | **2026** | **2025** |
| Net income | $49740 | $26365 | $215201 | $96703 |
| &nbsp;&nbsp;&nbsp;Interest income | (2768) | (3033) | (11729) | (13914) |
| &nbsp;&nbsp;&nbsp;Interest expense | 13269 | 15257 | 57131 | 60634 |
| &nbsp;&nbsp;&nbsp;Income tax provision | 11159 | 3596 | 62231 | 19331 |
| &nbsp;&nbsp;&nbsp;Depreciation and amortization | 11733 | 12180 | 46703 | 50573 |
| &nbsp;&nbsp;&nbsp;Amortization of acquired intangible assets | 26948 | 27002 | 107953 | 111878 |
| &nbsp;&nbsp;&nbsp;Stock-based compensation expense | 19117 | 21708 | 73063 | 96425 |
| &nbsp;&nbsp;&nbsp;Merger integration expenses | 1324 | 2178 | 5024 | 40535 |
| &nbsp;&nbsp;&nbsp;Amortization of incremental costs to obtain a contract | 1981 | 1730 | 7840 | 6745 |
| &nbsp;&nbsp;&nbsp;Costs associated with unused office space | 716 | 836 | 2945 | 3244 |
| &nbsp;&nbsp;&nbsp;Other | (329) | (35) | (378) | (403) |
| Adjusted EBITDA | $132890 | $107784 | $565984 | $471751 |

---

------

**Reconciliation of net income outlook to Adjusted EBITDA outlook (unaudited)**

---

| | |
|:---|:---|
|<br>**(in millions)** | **Outlook for the year ending**<br>**January 31, 2027** |
| Net income | $239 - 246 |
| &nbsp;&nbsp;&nbsp;Interest income | (8) |
| &nbsp;&nbsp;&nbsp;Interest expense | 46 |
| &nbsp;&nbsp;&nbsp;Income tax provision | 85 - 88 |
| &nbsp;&nbsp;&nbsp;Depreciation and amortization | 48 |
| &nbsp;&nbsp;&nbsp;Amortization of acquired intangible assets | 103 |
| &nbsp;&nbsp;&nbsp;Stock-based compensation expense | 89 |
| &nbsp;&nbsp;&nbsp;Merger integration expenses | 5 |
| &nbsp;&nbsp;&nbsp;Amortization of incremental costs to obtain a contract | 9 |
| &nbsp;&nbsp;&nbsp;Costs associated with unused office space | 2 |
| Adjusted EBITDA | $618 - 628 |

---

**Reconciliation of net income to non-GAAP net income (unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three months ended January 31,** | **Three months ended January 31,** | **Year ended January 31,** | **Year ended January 31,** |
|<br>**(in thousands, except per share data)** | **2026** | **2025** | **2026** | **2025** |
| Net income | $49740 | $26365 | $215201 | $96703 |
| Income tax provision | 11159 | 3596 | 62231 | 19331 |
| Income before income taxes - GAAP | 60899 | 29961 | 277432 | 116034 |
| &nbsp;&nbsp;&nbsp;Non-GAAP adjustments: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Amortization of acquired intangible assets | 26948 | 27002 | 107953 | 111878 |
| &nbsp;&nbsp;&nbsp;Stock-based compensation expense | 19117 | 21708 | 73063 | 96425 |
| &nbsp;&nbsp;&nbsp;Merger integration expenses | 1324 | 2178 | 5024 | 40535 |
| &nbsp;&nbsp;&nbsp;Costs associated with unused office space | 716 | 836 | 2945 | 3244 |
| &nbsp;&nbsp;&nbsp;Loss on extinguishment of debt |  |  |  | 1576 |
| Total adjustments to income before income taxes - GAAP | 48105 | 51724 | 188985 | 253658 |
| Income before income taxes - Non-GAAP | 109004 | 81685 | 466417 | 369692 |
| Income tax provision - Non-GAAP (1) | 27251 | 20421 | 116604 | 92423 |
| Non-GAAP net income | 81753 | 61264 | 349813 | 277269 |
| Diluted weighted-average shares | 86290 | 88614 | 87473 | 88828 |
| GAAP net income per diluted share | $0.58 | $0.30 | $2.46 | $1.09 |
| Non-GAAP net income per diluted share | $0.95 | $0.69 | $4.00 | $3.12 |

---

(1)The Company utilizes a normalized non-GAAP tax rate to provide better consistency across the interim reporting periods within a given fiscal year by eliminating the effects of non-recurring and period-specific items, which can vary in size and frequency, and which are not necessarily reflective of the Company's longer-term operations. The normalized non-GAAP tax rate applied to each period presented was 25%. The Company may adjust its non-GAAP tax rate as additional information becomes available and in conjunction with any other significant events occurring that may materially affect this rate, such as merger and acquisition activity, changes in business outlook, or other changes in expectations regarding tax regulations.

------

**Reconciliation of net income outlook to non-GAAP net income outlook (unaudited)**

---

| | |
|:---|:---|
|<br>**(in millions, except per share data)** | **Outlook for the year ending**<br>**January 31, 2027** |
| Net income | $239 - 246 |
| Income tax provision | 85 - 88 |
| Income before income taxes - GAAP | 324 - 334 |
| &nbsp;&nbsp;&nbsp;Non-GAAP adjustments: |  |
| &nbsp;&nbsp;&nbsp;Amortization of acquired intangible assets | 103 |
| &nbsp;&nbsp;&nbsp;Stock-based compensation expense | 89 |
| &nbsp;&nbsp;&nbsp;Merger integration expenses | 5 |
| &nbsp;&nbsp;&nbsp;Costs associated with unused office space | 2 |
| Total adjustments to income before income taxes - GAAP | 199 |
| Income before income taxes - Non-GAAP | 523 - 533 |
| Income tax provision - Non-GAAP (1) | 131 - 133 |
| Non-GAAP net income | $392 - 400 |
| Diluted weighted-average shares | 86 |
| GAAP net income per diluted share (2) | $2.78 - 2.85 |
| Non-GAAP net income per diluted share (2) | $4.56 - 4.65 |

---

(1)The Company utilizes a normalized non-GAAP tax rate to provide better consistency across the interim reporting periods within a given fiscal year by eliminating the effects of non-recurring and period-specific items, which can vary in size and frequency, and which are not necessarily reflective of the Company's longer-term operations. The normalized non-GAAP tax rate applied to each period presented was 25%. The Company may adjust its non-GAAP tax rate as additional information becomes available and in conjunction with any other significant events occurring that may materially affect this rate, such as merger and acquisition activity, changes in business outlook, or other changes in expectations regarding tax regulations.

(2)GAAP and Non-GAAP net income per diluted share may not calculate due to rounding.

**Certain terms**

---

| | |
|:---|:---|
| **Term** | **Definition** |
| HSA | A financial account through which consumers spend and save long-term for healthcare on a tax-advantaged basis. |
| CDB | Consumer-directed benefits offered by employers, including flexible spending and health reimbursement arrangements ("FSAs" and "HRAs"), Consolidated Omnibus Budget Reconciliation Act ("COBRA") administration, commuter and other benefits. |
| HSA member | Consumers with HSAs that we serve. |
| Total HSA Assets | HSA members' custodial cash assets held by our federally insured depository partners and our insurance company partners. Total HSA Assets also includes HSA members' investments in mutual funds through our custodial investment fund partner. |
| Client | Our employer clients. |
| Total Accounts | The sum of HSAs and CDBs on our platforms. |
| Client-held funds | Deposits held on behalf of our Clients to facilitate administration of our CDBs. |
| Network Partner | Our health plan partners, benefits administrators, and retirement plan recordkeepers. |
| Adjusted EBITDA | Earnings before interest, taxes, depreciation and amortization, amortization of acquired intangible assets, stock-based compensation expense, merger integration expenses, acquisition costs, gains and losses on equity securities, amortization of incremental costs to obtain a contract, costs associated with unused office space, and certain other non-operating items. |
| Non-GAAP net income | Calculated by adding back to GAAP net income before income taxes the following items: amortization of acquired intangible assets, stock-based compensation expense, merger integration expenses, acquisition costs, gains and losses on equity securities, costs associated with unused office space, and losses on extinguishment of debt, and subtracting a non-GAAP tax provision using a normalized non-GAAP tax rate. |
| Non-GAAP net income per diluted share | Calculated by dividing non-GAAP net income by diluted weighted-average shares outstanding. |

---